In an attempt to identify additional glioma cell lines that show ALT hallmarks after ATRX loss, we stably knocked down ATRX in SF295, CHLA-200, and KNS42, cell lines in which we were unable to recover CRISPR-mediated ATRX knockouts. The gene discussed is GPT; the disease is central nervous system cancer.